Effectiveness of recombinant Mycobacterium tuberculosis fusion protein skin test in screening for latent tuberculosis infection among HIV/AIDS patients
WANG Hui1, LI Jincheng1, LU Xing2, WANG Jinfu2, ZHU Limei3, LIU Qiao3
1. Department of Chronic Infectious Disease Control and Prevention, Yangzhou Center for Disease Control and Prevention, Yangzhou, Jiangsu 225000, China; 2. The Third People's Hospital of Yangzhou, Yangzhou, Jiangsu 225000, China; 3. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210000, China
Abstract：Objective To evaluate the effectiveness of recombinant Mycobacterium tuberculosis fusion protein skin test (EC-ST) in screening for latent tuberculosis infection (LTBI) among HIV/AIDS patients, so as to provide insights into the applicability of EC-ST in LTBI screening among HIV/AIDS patients. Methods From April to June 2023, HIV/AIDS patients under management and treatment in Yangzhou City, Jiangsu Province, were selected as study subjects. Basic information was collected through questionnaire surveys. LTBI was screened by EC-ST and interferon-gamma release assay (IGRA). Taking IGRA results as the diagnostic standard, the positive rate, sensitivity, specificity and consistency rate of EC-ST, and the impact of CD4+T lymphocyte (CD4) counts on the screening effect of EC-ST were analyzed. Results A total of 523 HIV/AIDS patients were screened, including 458 males (87.57%) and 65 females (12.43%). The median age was 48.00 (interquartile range, 21.00) years. The positive rate of EC-ST was 7.27% and the positive rate of IGRA was 7.46%, with no statistically significant difference (P>0.05). The consistency rate of the two methods was 94.84%, and the Kappa value of 0.621 (95%CI: 0.489-0.752, P<0.05). The sensitivity of EC-ST was 64.10% and the specificity was 97.31%. Comparing the groups with CD4 counts <500 and ≥500 cells/μL, the consistency rates of the two methods were 95.32% and 94.44%, and the Kappa values were 0.568 and 0.650, respectively (both P<0.05). There were no statistically significant differences in the positive rates, sensitivity, and specificity of EC-ST (all P>0.05). Comparing the groups with CD4 counts <200 and ≥200 cells/μL, the consistency rates of the two methods were 96.55% and 94.62%, and the Kappa values were 0.648 and 0.619, respectively (both P<0.05). There were no statistically significant differences in the positive rates, sensitivity, and specificity of EC-ST (all P>0.05). Conclusion The effectiveness of EC-ST in screening for LTBI among HIV/AIDS patients is consistent with that of IGRA and is not affected by CD4 counts.
王慧, 李锦成, 陆兴, 王金富, 竺丽梅, 刘巧. 重组结核杆菌融合蛋白皮肤试验筛查HIV/AIDS病例结核分枝杆菌潜伏感染的效果分析[J]. 预防医学, 2024, 36(7): 639-643.
WANG Hui, LI Jincheng, LU Xing, WANG Jinfu, ZHU Limei, LIU Qiao. Effectiveness of recombinant Mycobacterium tuberculosis fusion protein skin test in screening for latent tuberculosis infection among HIV/AIDS patients. Preventive Medicine, 2024, 36(7): 639-643.
[1] World Health Organization.Global tuberculosis report 2023[R].Geneva:WHO,2023. [2] 沈银忠,卢洪洲,陈耀凯,等.人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J].新发传染病电子杂志,2022,7(1):73-87. [3] 桑国鑫,陈同,车洋,等.宁波市结核分枝杆菌和艾滋病病毒双重感染筛查结果[J].预防医学,2022,34(11):1121-1124. [4] OVERTON K,VARMA R,POST J J.Comparison of interferon-γ release assays and the tuberculin skin test for diagnosis of tuberculosis in human immunodeficiency virus:a systematic review[J].Tuberc Respir Dis(Seoul),2018,81(1):59-72. [5] BINAY U D,FINCANCI M,FERSAN E,et al.Comparison of tuberculin skin test(TST)and T-SPOT.TB Tests for diagnosis of latent tuberculosis infection(LTBI)in HIV-infected patients[J].Mikrobiyol Bul,2019,53(4):388-400. [6] XIA L,XU M,LI F,et al.High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection:a phase Ⅲ,multi-centered,double-blind,hospital-based,randomized controlled trial[J].Int J Infect Dis,2023,126:98-103. [7] 沈银忠,李太生.《中国艾滋病诊疗指南(2021年版)》解读[J].国际流行病学传染病学杂志,2022,49(2):81-85. [8] 唐锦华,姜申,黄嫄,等.QuantiFERON-TB Gold Plus鉴别活动性结核病与潜伏性结核感染的潜在价值探讨[J].中华检验医学杂志,2020,43(9):907-911. [9] 卢鹏,刘巧,竺丽梅,等.中国东部地区结核菌素试验诊断结核病感染临界值的确定:基于人群的现况调查[J].中华流行病学杂志,2020,41(3):363-367. [10] 中华人民共和国国家卫生健康委员会.艾滋病和艾滋病病毒感染诊断WS 293—2019[S].2019. [11] MATULYTE E,KANCAUSKIENE Z,KAUSAS A,et al.Latent tuberculosis infection and associated risk factors among people living with HIV and HIV-uninfected individuals in Lithuania[J].Pathogens,2023,12(8):1-13. [12] KLAUTAU G B,DA MOTA N V F,SALLES M J C,et al.Interferon-γrelease assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV:a cross-sectional study[J].BMC Infect Dis,2018,18(1):1-8. [13] MAZUREK G H,JEREB J,LOBUE P,et al.Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection,United States[J].MMWR Recomm Rep,2005,54(15):49-55. [14] 马艳,陆伟,高磊,等.终止结核病流行须加强结核分枝杆菌潜伏感染高危人群筛查和预防性治疗的管理[J].中国防痨杂志,2022,44(3):209-214. [15] LI F,XU M,QIN C,et al.Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis:an open-label,randomized,two-centre phase 2a clinical trial[J].Clin Microbiol Infect,2016,22(10):9-16. [16] XU M,LU W,LI T,et al.Sensitivity,specificity,and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China:two randomized,self-controlled,parallel-group phase 2b trials[J].Clin Infect Dis,2022,74(4):668-677. [17] LU P,WU K,ZHOU H,et al.Evaluation of ESAT6-CFP10 skin test for Mycobacterium tuberculosis infection among persons living with HIV in China[J].J Clin Microbiol,2023,61(4):1-10. [18] SINGH R,FATIMA N,SHUKLA I,et al.Evaluation of role of interferon gamma release assays in the diagnosis of latent tuberculosis in human immunodeficiency virus-infected patients[J].Indian J Sex Transm Dis AIDS,2021,42(2):111-117. [19] 张瑜,卢鹏,陆伟,等.潜伏结核感染三种检测方法比较的研究进展[J].中国热带医学,2022,22(5):477-482. [20] 苏倩,汪清雅,张婷,等.重组结核分枝杆菌融合蛋白皮肤试验与TST在学校结核潜伏感染筛查中的比较[J].中国感染控制杂志,2023,22(5):547-551.
